RxDoctor Payments Data

Adrianne Mallen, MD

Gynecologic Oncology · Saint Louis Park, MNNPI 1831535558

Payments from drug & device makers

What this record shows

This record is dominated by grants: $1,683 of the $2,485 with a category attached, or 67.7%. AstraZeneca accounts for 75.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $1,840 and has fallen 92.2% since, to $143 in 2025.

$2,485in general payments, 2019–2025

Across 17 payments — averaging $146.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$204
  • Tesaro, Inc.$123
  • Coopersurgical, Inc.$120
  • GSK$103
  • Intuitive Surgical$24
  • plus $46 from 2 others

What the payments were for

  • Grants$1,68368%
  • Food & beverage$75830%
  • Education$442%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca5$1,865
AbbVie5$204
Tesaro, Inc.1$123
Coopersurgical, Inc.1$120
GSK1$103
Intuitive Surgical2$24
Boston Scientific1$23
On Target Laboratories, Inc1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,485 in reported general payments places this provider in the 70th percentile of 39 gynecologic oncology providers in Minnesota.

See all gynecologic oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$100,797
Medicare patients
112
Services billed
1,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Olanzapine36$437
Prochlorperazine Maleate34$379
Letrozole12$172
Dexamethasone12$159
Oxycodone Hcl12$53

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Saint Louis Park

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →